Status:
COMPLETED
Muscle Function and Its Biological and Physiological Determinants in Sickle Cell Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
15-60 years
Phase:
NA
Brief Summary
Background : Sickle cell patients have profound remodeling of their muscle microcirculation networks with signs of amyotrophy. However, the consequences of these muscle alterations on the functional s...
Eligibility Criteria
Inclusion
- For Sickle cell patients :
- age ≥ 15 and \< 60 years old,
- SS homozygote or SC heterozygote
- in clinical steady state (i.e. without vaso-occlusive crisis or recent blood transfusion)
- identified by systematic neonatal screening programs,
- registered in the French medical social security national program
- For Healthy and non sickle cell subjects:
- age ≥ 18 and \< 60 years old
- without cardiovascular/respiratory/muscle disease,
- registered in the French medical social security national program.
Exclusion
- other hemoglobinopathies,
- stroke or vasculopathy history,
- presence of leg ulcers or osteonecrosis,
- recent infectious episode (less than 1 month),
- chronic transfusion therapy programs,
- recent blood transfusion or phlebotomies (less than 3 months),
- patients not at steady state,
- pregnancy or breast feeding
Key Trial Info
Start Date :
September 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2019
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT03243812
Start Date
September 15 2017
End Date
December 13 2019
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, France, 69003